Lung cancer is the leading cause of cancer death in the world, with non-small cell lung cancer (NSCLC) a significant component of those deaths.1,2 Treatments for advanced-stage NSCLC, however, are limited. Erlotinib, a small-molecule tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), has aided in advancing NSCLC therapy. Erlotinib has been shown to increase survival by 2 months compared with placebo in a phase 3, randomized controlled trial when used as second- or third-line therapy.3 The authors present a case of a man surviving almost 8 years with late-stage NSCLC on treatment with erlotinib at the VA West Los Angeles Medical Center (WLAMC).
Clinical Topics & News
Long-Term Survival of a Patient With Late-Stage Non-Small Cell Lung Cancer
After not responding to chemotherapy and monoclonal antibody therapy, a patient with late-stage non-small cell lung cancer benefited from treatment with erlotinib.
Clinical Topics
-
Despite benefits, extended-interval pembro uptake remains low -
Time to cancer diagnoses in U.S. averages 5 months -
Opioids after lung cancer surgery may up all-cause mortality risk -
Gene mutations may drive lung cancer in never-smokers -
Reporting Coronary Artery Calcium on Low-Dose Computed Tomography Impacts Statin Management in a Lung Cancer Screening Population
Digital Edition
Multimedia
Conference Coverage
-
Multiprong strategy makes clinical trials less White -
CBSM phone app eases anxiety, depression in cancer patients -
T-DXd active in many solid tumors; ‘shift in thinking’ -
Huge underuse of germline testing for cancer patients -
Reducing risk for thrombosis in patients with lung cancer -
ACS officer provides ASCO highlights: Targeting hidden cancer, AI in oncology -
SCLC: Bispecific antibody shows phase 1 promise -
Durvalumab pre, post surgery in NSCLC: Practice changing? -
Study gives new insight into timing of combo treatment in metastatic NSCLC -
First target doesn’t affect survival in NSCLC with brain metastases
Question 1 of 5
